Skin response to a carcinogen involves the xenobiotic receptor pregnane X receptor

Experimental Dermatology

Volumn 24, Issue 11, 2015, Pages 835-840

  Elentner, Andreas ^a   Ortner, Daniela ^a   Clausen, Björn ^b   Gonzalez, Frank J ^c   Fernández Salguero, Pedro M ^d   Schmuth, Matthias ^a   Dubrac, Sandrine ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

DNA damage; H2AX; Langerhans cells; Pregnane X receptor; Skin

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; AROMATIC HYDROCARBON RECEPTOR; CARCINOGEN; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 3A11; PREGNANE X RECEPTOR; XENOBIOTIC AGENT; STEROID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DNA DAMAGE; EPIDERMIS CELL; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; METABOLIC ACTIVATION; MOUSE; NONHUMAN; SKIN FUNCTION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL MOTION; DRUG EFFECTS; METABOLISM; SKIN;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CELL MOVEMENT; DNA DAMAGE; LANGERHANS CELLS; MICE, INBRED C57BL; RECEPTORS, STEROID; SKIN; UP-REGULATION;

EID: 84946602363     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12766     Document Type: Article

References (47)

1. Trempus C, Morris R, Ehinger M et al. Cancer Res 2007: 67: 4173-4181.
2. Kleiner H, Vulimiri S, Hatten W et al. Chem Res Toxicol 2004: 17: 1667-1674.
3. Morris R, Tryson K, Wu K. Cancer Res 2000: 60: 226-229.
4. Luckert C, Ehlers A, Buhrke T et al. Toxicol Lett 2013: 222: 180-188.
5. Nebert D, Dalton T. Nat Rev Cancer 2006: 6: 947-960.
6. Kumagai T, Suzuki H, Sasaki T et al. Drug Metab Pharmacokinet 2012: 27: 200-206.
7. Gálvez-Peralta M, Shi Z, Chen J et al. Int J Cancer 2013: 132: 2065-2075.
8. Maglich J, Stoltz C M, Goodwin B et al. Mol Pharmacol 2002: 62: 638-646.
9. Kliewer S, Goodwin B, Willson T M. Endocr Rev 2002: 23: 687-702.
10. Sonoda J, Rosenfeld J M, Xu L et al. Curr Drug Metab 2003: 4: 59-72.
11. Vignati L, Bogni A, Grossi P et al. Toxicology 2004: 199: 23-33.
12. Schote A, Turner J D, Schiltz J et al. Mol Immunol 2007: 44: 1436-1445.
13. Jeannesson E, Siest G, Herbeth B et al. Drug Metabol Drug Interact 2011: 26: 27-32.
14. Siest G, Jeannesson E, Marteau J B et al. Drug Metab Dispos 2008: 36: 182-189.
15. Dubrac S, Elentner A, Ebner S et al. J Immunol 2010: 184: 2949-2957.
16. Igyártó B, Kaplan D. Curr Opin Immunol 2013: 25: 115-119.
17. Romani N, Clausen B E, Stoitzner P. Immunol Rev 2010: 234: 120-141.
18. Roychowdhury S, Svensson C. AAPS J 2005: 7: E834-E846.
19. Modi B, Neustadter J, Binda E et al. Science 2012: 335: 104-108.
20. Woods G, Qu M, Ragg S J et al. Immunology 1996: 88: 134-139.
21. Qu M, Muller H K, Woods G M. Carcinogenesis 1997: 18: 1277-1279.
22. Chen Y, Tang Y, Guo C et al. Biochem Pharmacol 2012: 83: 1112-1126.
23. Nebert D, Shi Z, Galvez-Peralta M et al. Mol Pharmacol 2013: 84: 304-313.
24. Slominski A, Zmijewski M, Skobowiat C et al. Adv Anat Embryol Cell Biol 2012: 212: 1-115.
25. Slominski A, Zmijewski M, Semak I et al. Anticancer Agents Med Chem 2014: 14: 77-96.
26. Staudinger J L, Goodwin B, Jones S A et al. Proc Natl Acad Sci U S A 2001: 98: 3369-3374.
27. Ma X, Cheung C, Krausz K W et al. Drug Metab Dispos 2008: 36: 2506-2512.
28. Fernandez-Salguero P, Pineau T, Hilbert D M et al. Science 1995: 268: 722-726.
29. Bennett C L, van Rijn E, Jung S et al. J Cell Biol 2005: 169: 569-576.
30. Dubrac S, Stoitzner P, Pirkebner D et al. J Immunol 2007: 178: 4362-4372.
31. Henri S, Poulin L F, Tamoutounour S et al. J Exp Med 2010: 207: 189-206.
32. Sharma A, Singh K, Almasan A. Methods Mol Biol 2012: 920: 613-626.
33. Moore J, Palep S, Saladi R et al. Photochem Photobiol 2004: 80: 587-595.
34. Kao G, McKenna W, Guenther M et al. J Cell Biol 2003: 160: 1017-1027.
35. Spiewak R. Ann Agric Environ Med 2001: 8: 1-5.
36. Gallagher R, Bajdik C D, Fincham S et al. Cancer Epidemiol Biomarkers Prev 1996: 5: 419-424.
37. Schwarz M, Münzel P A, Braeuning A. Arch Toxicol 2013: 87: 783-798.
38. Koutsounas I, Patsouris E, Theocharis S. Histol Histopathol 2013: 28: 405-420.
39. Jux B, Kadow S, Esser C. J Immunol 2009: 182: 6709-6717.
40. Götz C, Pfeiffer R, Tigges J et al. Exp Dermatol 2012: 21: 358-363.
41. Haslam I, Pitre A, Schuetz J et al. Trends Pharmacol Sci 2013: 34: 599-604.
42. Götz C, Pfeiffer R, Tigges J et al. Exp Dermatol 2012: 21: 364-369.
43. Slominski A, Li W, Kim T et al. J Steroid Biochem Mol Biol 2014: doi: 10.1016/j.jsbmb.2014.11.010.
44. Piipari R, Savela K, Nurminen T et al. Int J Cancer 2000: 86: 610-616.
45. Muller H, Dandie G W, Ragg S J et al. In Vivo 1993: 7: 293-296.
46. Fujita H, Suárez-Fariñas M, Mitsui H et al. J Invest Dermatol 2012: 132: 1645-1655.
47. Yusuf N, Nasti T H, Katiyar S K et al. Cancer Res 2008: 68: 3924-3930.